Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Eric Wu

Concepts (464)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
31
2022
425
4.040
 Why?
Hyperkalemia
4
2021
35
2.470
 Why?
Everolimus
10
2016
112
2.280
 Why?
Health Resources
10
2026
130
2.270
 Why?
Cost of Illness
13
2022
322
1.970
 Why?
Health Services
11
2016
114
1.460
 Why?
Breast Neoplasms
16
2018
2365
1.450
 Why?
Antineoplastic Agents
20
2018
2201
1.410
 Why?
Citalopram
6
2012
32
1.190
 Why?
Receptors, Antigen, T-Cell
4
2021
667
1.130
 Why?
Health Expenditures
9
2020
194
1.110
 Why?
Receptors, Estrogen
3
2015
400
1.110
 Why?
Medication Adherence
4
2015
540
1.030
 Why?
Psoriasis
5
2018
113
0.990
 Why?
Immunotherapy, Adoptive
2
2020
339
0.970
 Why?
Insurance Claim Review
18
2017
83
0.950
 Why?
Practice Patterns, Physicians'
6
2018
1360
0.940
 Why?
United States
52
2022
16018
0.930
 Why?
Hepatitis C, Chronic
3
2019
152
0.910
 Why?
Pyrimidines
7
2014
519
0.870
 Why?
Renal Insufficiency, Chronic
3
2021
657
0.870
 Why?
Middle Aged
76
2026
35971
0.860
 Why?
Drug Substitution
3
2019
63
0.860
 Why?
Piperazines
6
2014
378
0.850
 Why?
Biosimilar Pharmaceuticals
2
2022
28
0.850
 Why?
Receptors, Progesterone
2
2015
243
0.820
 Why?
Attention Deficit Disorder with Hyperactivity
4
2012
423
0.790
 Why?
Aged
57
2026
25955
0.780
 Why?
Retrospective Studies
46
2026
17149
0.770
 Why?
Models, Economic
2
2020
61
0.770
 Why?
Comparative Effectiveness Research
3
2012
167
0.750
 Why?
Benzamides
6
2014
224
0.750
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
2014
127
0.740
 Why?
Humans
123
2026
144667
0.730
 Why?
Antifungal Agents
4
2017
150
0.730
 Why?
Cost-Benefit Analysis
15
2022
638
0.710
 Why?
Female
93
2026
78304
0.710
 Why?
Imatinib Mesylate
7
2014
76
0.700
 Why?
Central Nervous System Stimulants
3
2012
185
0.690
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
192
0.670
 Why?
Hospital Costs
3
2020
125
0.660
 Why?
Gout
2
2012
35
0.650
 Why?
Rheumatology
1
2022
133
0.650
 Why?
Adult
58
2026
40489
0.640
 Why?
Male
79
2026
72431
0.640
 Why?
Acidosis
1
2021
105
0.640
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
293
0.630
 Why?
Proportional Hazards Models
14
2017
1322
0.620
 Why?
Hypoglycemic Agents
4
2015
1388
0.620
 Why?
Kaplan-Meier Estimate
12
2018
967
0.610
 Why?
Nocturia
1
2019
8
0.610
 Why?
Antineoplastic Combined Chemotherapy Protocols
11
2018
1961
0.600
 Why?
Antibodies, Monoclonal
7
2018
1505
0.600
 Why?
Databases, Factual
13
2021
1494
0.590
 Why?
Prevalence
11
2021
2839
0.580
 Why?
Postmenopause
7
2018
390
0.570
 Why?
Comorbidity
12
2014
1652
0.550
 Why?
Hospitalization
15
2021
2446
0.550
 Why?
Medicare
10
2022
899
0.540
 Why?
Nutrition Surveys
1
2019
280
0.540
 Why?
Proline
2
2015
82
0.530
 Why?
Candida
2
2017
45
0.530
 Why?
Leukemia, Myeloid, Chronic-Phase
2
2014
3
0.520
 Why?
Fluconazole
1
2017
23
0.510
 Why?
Protein Kinase Inhibitors
5
2014
971
0.510
 Why?
Candidemia
1
2017
15
0.510
 Why?
Cardiologists
1
2017
47
0.500
 Why?
Myocardial Perfusion Imaging
1
2017
49
0.500
 Why?
Fees, Pharmaceutical
3
2016
8
0.500
 Why?
Tomography, Emission-Computed, Single-Photon
1
2017
104
0.490
 Why?
Oligopeptides
2
2015
266
0.490
 Why?
Aftercare
2
2021
222
0.480
 Why?
Diabetes Mellitus, Type 2
5
2015
2573
0.470
 Why?
Thrombolytic Therapy
1
2017
161
0.470
 Why?
Cystitis, Interstitial
2
2006
20
0.470
 Why?
Biological Therapy
1
2016
28
0.470
 Why?
Antidepressive Agents, Second-Generation
3
2011
44
0.470
 Why?
Antiviral Agents
3
2019
765
0.460
 Why?
Antirheumatic Agents
2
2016
304
0.460
 Why?
Neoplasm Recurrence, Local
4
2026
1145
0.460
 Why?
Tissue Plasminogen Activator
1
2017
244
0.450
 Why?
Drug Eruptions
1
2015
28
0.450
 Why?
Propylamines
2
2012
11
0.430
 Why?
Costs and Cost Analysis
10
2019
221
0.430
 Why?
Fibrinolytic Agents
1
2017
290
0.420
 Why?
Physicians, Primary Care
1
2017
209
0.420
 Why?
Gastrointestinal Stromal Tumors
1
2014
40
0.420
 Why?
Methylphenidate
2
2012
49
0.420
 Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
338
0.420
 Why?
Diphosphonates
2
2012
68
0.420
 Why?
Delivery of Health Care
2
2019
944
0.420
 Why?
Health Care Rationing
2
2016
56
0.410
 Why?
Insulin
3
2015
2502
0.410
 Why?
Patient Acceptance of Health Care
8
2026
881
0.400
 Why?
Anemia
1
2015
189
0.400
 Why?
Brain Ischemia
1
2017
358
0.400
 Why?
Treatment Outcome
24
2021
11735
0.390
 Why?
Imidazoles
2
2012
246
0.390
 Why?
Hypertension
5
2018
1262
0.390
 Why?
Insurance, Health
5
2011
308
0.380
 Why?
Neoplasm Metastasis
8
2018
691
0.380
 Why?
Dextroamphetamine
1
2012
4
0.370
 Why?
Aged, 80 and over
14
2020
8284
0.370
 Why?
Antineoplastic Agents, Hormonal
4
2016
192
0.370
 Why?
Guanfacine
1
2012
5
0.370
 Why?
Pharmacoepidemiology
1
2012
22
0.360
 Why?
Liver Neoplasms
2
2015
777
0.350
 Why?
Attention Deficit and Disruptive Behavior Disorders
1
2012
56
0.350
 Why?
Schizophrenia
2
2006
443
0.350
 Why?
Patient Compliance
3
2011
587
0.350
 Why?
Medicaid
3
2012
464
0.340
 Why?
Pulmonary Embolism
1
2014
241
0.340
 Why?
Drug Delivery Systems
1
2015
380
0.340
 Why?
Drug Costs
6
2015
117
0.340
 Why?
Fumarates
1
2011
10
0.330
 Why?
Disease-Free Survival
7
2019
768
0.330
 Why?
Antibodies, Monoclonal, Humanized
9
2018
990
0.330
 Why?
Drugs, Generic
1
2011
27
0.330
 Why?
Referral and Consultation
1
2017
852
0.330
 Why?
Bone Diseases
1
2011
61
0.320
 Why?
Amides
1
2011
99
0.310
 Why?
Triazoles
4
2016
184
0.310
 Why?
Angiotensin Receptor Antagonists
1
2011
115
0.310
 Why?
Stroke
2
2017
1262
0.300
 Why?
Drug Monitoring
4
2016
396
0.300
 Why?
Venous Thromboembolism
1
2014
326
0.300
 Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
228
0.300
 Why?
Arthritis, Rheumatoid
2
2016
1170
0.300
 Why?
Tumor Necrosis Factor-alpha
5
2022
1207
0.300
 Why?
Potassium
2
2021
152
0.290
 Why?
Crohn Disease
5
2012
259
0.290
 Why?
Sick Leave
2
2007
16
0.290
 Why?
Heart Failure
3
2020
2324
0.290
 Why?
Diabetes Mellitus
1
2018
1076
0.290
 Why?
Hyperuricemia
1
2009
47
0.290
 Why?
Myelodysplastic Syndromes
2
2021
147
0.290
 Why?
Anticoagulants
1
2014
729
0.280
 Why?
Oligonucleotides
2
2019
151
0.270
 Why?
Absenteeism
2
2005
52
0.270
 Why?
Uric Acid
1
2009
166
0.270
 Why?
Quality of Life
9
2021
3183
0.270
 Why?
Risk Factors
12
2017
10796
0.260
 Why?
Insurance Claim Reporting
2
2007
26
0.260
 Why?
Multiple Myeloma
1
2011
306
0.260
 Why?
Randomized Controlled Trials as Topic
3
2012
1742
0.250
 Why?
Head and Neck Neoplasms
1
2012
562
0.250
 Why?
Physicians
1
2015
949
0.250
 Why?
Hypoglycemia
1
2012
479
0.250
 Why?
Leukemia, Myeloid, Acute
2
2026
685
0.250
 Why?
Health Status Indicators
1
2007
167
0.250
 Why?
Young Adult
14
2026
14122
0.240
 Why?
Drug Therapy, Combination
6
2019
1044
0.240
 Why?
Pentosan Sulfuric Polyester
1
2006
2
0.240
 Why?
Economics, Pharmaceutical
1
2006
10
0.240
 Why?
Drug Resistance, Fungal
2
2017
7
0.230
 Why?
fms-Like Tyrosine Kinase 3
1
2026
50
0.230
 Why?
Treatment Failure
3
2017
365
0.230
 Why?
Endometriosis
2
2017
57
0.220
 Why?
Adolescent
22
2026
22409
0.220
 Why?
Urinary Incontinence
1
2005
64
0.210
 Why?
Diagnostic Errors
1
2006
177
0.210
 Why?
Prostatic Neoplasms
2
2012
978
0.210
 Why?
Nitriles
3
2016
205
0.210
 Why?
Immunoglobulin G
1
2008
886
0.210
 Why?
Recurrence
3
2020
1136
0.200
 Why?
Electronic Health Records
2
2021
1176
0.200
 Why?
Emergency Service, Hospital
4
2021
2325
0.200
 Why?
Protein-Tyrosine Kinases
4
2014
431
0.190
 Why?
Antihypertensive Agents
3
2012
512
0.190
 Why?
Psychotic Disorders
1
2005
185
0.190
 Why?
Molecular Targeted Therapy
3
2015
437
0.190
 Why?
Genetic Therapy
2
2021
313
0.180
 Why?
Thiophenes
2
2014
121
0.180
 Why?
Infliximab
1
2022
111
0.180
 Why?
Delayed-Action Preparations
3
2017
184
0.180
 Why?
Population Surveillance
1
2005
484
0.180
 Why?
Anti-Inflammatory Agents
3
2011
477
0.170
 Why?
Giant Cell Tumor of Tendon Sheath
1
2021
8
0.170
 Why?
Bone Density Conservation Agents
2
2012
81
0.170
 Why?
Gout Suppressants
2
2012
20
0.170
 Why?
Gastritis
1
2022
116
0.170
 Why?
Enteritis
1
2022
104
0.170
 Why?
Carcinoma, Non-Small-Cell Lung
3
2015
1186
0.160
 Why?
Biological Products
2
2016
256
0.160
 Why?
Severity of Illness Index
6
2018
2922
0.160
 Why?
Polymerase Chain Reaction
2
2014
1047
0.160
 Why?
Hemophilia B
1
2021
65
0.160
 Why?
Antimetabolites, Antineoplastic
1
2021
105
0.160
 Why?
Atomoxetine Hydrochloride
2
2012
8
0.160
 Why?
Bronchodilator Agents
2
2011
184
0.160
 Why?
Adenocarcinoma
1
2007
923
0.160
 Why?
Time Factors
5
2017
7140
0.160
 Why?
Voriconazole
2
2016
21
0.150
 Why?
Immunologic Factors
1
2022
259
0.150
 Why?
Eosinophilia
1
2022
222
0.150
 Why?
National Health Programs
1
2019
23
0.150
 Why?
Regression Analysis
4
2012
998
0.150
 Why?
Technology Assessment, Biomedical
1
2019
44
0.150
 Why?
Pulmonary Disease, Chronic Obstructive
3
2011
919
0.150
 Why?
Muscular Atrophy, Spinal
1
2019
25
0.150
 Why?
Aromatase Inhibitors
2
2018
74
0.150
 Why?
Hemophilia A
1
2021
147
0.150
 Why?
Patient Readmission
2
2017
765
0.150
 Why?
Atrial Fibrillation
1
2005
555
0.150
 Why?
Survival of Motor Neuron 1 Protein
1
2019
13
0.150
 Why?
Health Services Research
1
2021
392
0.150
 Why?
Spinal Muscular Atrophies of Childhood
1
2019
18
0.150
 Why?
Survival Analysis
4
2018
1370
0.140
 Why?
Multivariate Analysis
5
2015
1537
0.140
 Why?
Microbial Sensitivity Tests
2
2017
373
0.140
 Why?
Urologic Neoplasms
1
2018
31
0.140
 Why?
China
2
2021
269
0.140
 Why?
Idiopathic Pulmonary Fibrosis
2
2015
691
0.140
 Why?
Aging
1
2009
1938
0.140
 Why?
Europe
3
2019
419
0.140
 Why?
Vital Capacity
2
2015
290
0.140
 Why?
Polystyrenes
1
2018
36
0.130
 Why?
Time-to-Treatment
2
2017
242
0.130
 Why?
Managed Care Programs
2
2010
140
0.130
 Why?
Antidepressive Agents
2
2011
248
0.130
 Why?
Chronic Disease
4
2014
1810
0.130
 Why?
4-Aminopyridine
1
2017
30
0.130
 Why?
Retreatment
1
2017
77
0.130
 Why?
Overweight
1
2022
606
0.130
 Why?
Thiazoles
2
2014
139
0.130
 Why?
Drug Administration Schedule
4
2013
779
0.120
 Why?
Aspergillosis
1
2016
24
0.120
 Why?
Chemotherapy, Adjuvant
2
2016
427
0.120
 Why?
Patient Preference
1
2019
226
0.120
 Why?
Abiraterone Acetate
1
2016
15
0.120
 Why?
Administration, Intravenous
1
2017
170
0.120
 Why?
Consumer Behavior
1
2017
70
0.120
 Why?
Hysterectomy
1
2017
137
0.120
 Why?
Administrative Claims, Healthcare
1
2016
28
0.120
 Why?
Mental Disorders
1
2005
1154
0.120
 Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
53
0.120
 Why?
Capecitabine
1
2016
57
0.120
 Why?
Trastuzumab
1
2016
117
0.110
 Why?
Prednisone
1
2016
221
0.110
 Why?
Disability Evaluation
1
2017
310
0.110
 Why?
Clinical Protocols
1
2017
282
0.110
 Why?
Androstadienes
1
2015
75
0.110
 Why?
Ki-1 Antigen
1
2015
7
0.110
 Why?
Patient Admission
1
2017
220
0.110
 Why?
International Classification of Diseases
1
2016
147
0.110
 Why?
Patient Discharge
1
2021
985
0.110
 Why?
Waiting Lists
1
2017
263
0.110
 Why?
Logistic Models
2
2014
2114
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
22
0.110
 Why?
Ribavirin
1
2015
80
0.110
 Why?
Drug Interactions
1
2016
401
0.110
 Why?
Ambulatory Care
3
2015
607
0.110
 Why?
Neoplasm Staging
2
2015
1465
0.110
 Why?
California
2
2006
471
0.100
 Why?
Carboplatin
1
2014
161
0.100
 Why?
International Normalized Ratio
1
2014
52
0.100
 Why?
Heparin, Low-Molecular-Weight
1
2014
36
0.100
 Why?
Amphotericin B
1
2014
36
0.100
 Why?
Cytogenetic Analysis
1
2013
33
0.100
 Why?
Recombinant Proteins
1
2017
1363
0.100
 Why?
Japan
3
2021
145
0.100
 Why?
Insurance, Health, Reimbursement
1
2014
97
0.100
 Why?
Cross-Sectional Studies
3
2019
5870
0.100
 Why?
Follow-Up Studies
5
2015
5414
0.100
 Why?
Drug Prescriptions
1
2015
283
0.100
 Why?
Models, Theoretical
1
2017
578
0.100
 Why?
Constipation
1
2014
98
0.100
 Why?
ErbB Receptors
2
2016
632
0.100
 Why?
Paclitaxel
1
2014
256
0.100
 Why?
Morpholines
1
2014
129
0.100
 Why?
Immunoconjugates
1
2015
138
0.100
 Why?
Receptor Protein-Tyrosine Kinases
1
2015
230
0.100
 Why?
Mycoses
1
2014
88
0.100
 Why?
Budgets
1
2012
14
0.100
 Why?
Recovery of Function
1
2017
715
0.090
 Why?
Hodgkin Disease
1
2015
171
0.090
 Why?
Drug Combinations
2
2011
393
0.090
 Why?
Warfarin
1
2014
173
0.090
 Why?
Allopurinol
1
2012
70
0.090
 Why?
Cohort Studies
5
2016
5957
0.090
 Why?
Adalimumab
5
2011
55
0.090
 Why?
Lisdexamfetamine Dimesylate
1
2012
8
0.090
 Why?
Laparoscopy
1
2017
477
0.090
 Why?
New Zealand
1
2012
54
0.090
 Why?
Gastrointestinal Diseases
1
2014
217
0.090
 Why?
Immunocompromised Host
1
2014
202
0.090
 Why?
Pyridines
1
2016
603
0.090
 Why?
Ethanolamines
1
2012
14
0.090
 Why?
Databases as Topic
2
2009
71
0.090
 Why?
Health Status
2
2008
834
0.090
 Why?
Benzopyrans
1
2012
30
0.090
 Why?
Genetic Testing
1
2015
480
0.090
 Why?
Clinical Trials as Topic
2
2019
1056
0.090
 Why?
Estradiol
1
2015
507
0.090
 Why?
Triple Negative Breast Neoplasms
1
2014
217
0.090
 Why?
Florida
1
2012
117
0.090
 Why?
Sulfonylurea Compounds
1
2012
51
0.090
 Why?
Multiple Sclerosis
1
2017
485
0.090
 Why?
Rivaroxaban
1
2014
268
0.090
 Why?
Pleural Effusion
1
2012
59
0.090
 Why?
Surveys and Questionnaires
4
2021
6041
0.090
 Why?
Neurotransmitter Uptake Inhibitors
1
2011
3
0.090
 Why?
Australia
1
2012
287
0.090
 Why?
Fractures, Spontaneous
1
2011
15
0.090
 Why?
North America
1
2012
312
0.080
 Why?
Cyclohexanols
1
2011
10
0.080
 Why?
Hypercalcemia
1
2011
22
0.080
 Why?
Lung Neoplasms
2
2015
2660
0.080
 Why?
Spinal Cord Compression
1
2011
22
0.080
 Why?
Child
6
2020
22600
0.080
 Why?
Nebulizers and Vaporizers
1
2011
62
0.080
 Why?
Drug Resistance, Neoplasm
2
2026
881
0.080
 Why?
Cost Sharing
1
2011
20
0.080
 Why?
Sirolimus
1
2012
280
0.080
 Why?
Efficiency
2
2011
104
0.080
 Why?
Adamantane
1
2011
18
0.080
 Why?
Models, Statistical
2
2012
677
0.080
 Why?
Bone Diseases, Metabolic
1
2011
58
0.080
 Why?
Case-Control Studies
3
2014
3603
0.080
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2011
46
0.080
 Why?
Communication
1
2017
972
0.080
 Why?
Norepinephrine
1
2011
196
0.080
 Why?
Health Benefit Plans, Employee
2
2009
25
0.080
 Why?
Bone Neoplasms
1
2012
255
0.080
 Why?
Pyrazines
1
2011
92
0.080
 Why?
Pyrrolidines
1
2011
123
0.080
 Why?
Angiogenesis Inhibitors
1
2011
238
0.070
 Why?
Linear Models
1
2012
845
0.070
 Why?
Administration, Oral
1
2012
851
0.070
 Why?
Gastrointestinal Agents
1
2009
65
0.070
 Why?
Drug Utilization
1
2010
167
0.070
 Why?
Etanercept
1
2008
60
0.070
 Why?
Serotonin
1
2011
294
0.070
 Why?
Obesity
1
2022
3070
0.070
 Why?
Blood Chemical Analysis
1
2009
109
0.070
 Why?
Receptors, Tumor Necrosis Factor
1
2008
161
0.070
 Why?
Age Distribution
3
2015
402
0.070
 Why?
Depressive Disorder
1
2011
386
0.070
 Why?
Amphetamines
1
2007
6
0.070
 Why?
Adrenergic Uptake Inhibitors
1
2007
14
0.070
 Why?
Insurance, Pharmaceutical Services
1
2007
24
0.070
 Why?
Employment
2
2007
184
0.060
 Why?
Digestive System Surgical Procedures
1
2008
110
0.060
 Why?
Medical Audit
1
2007
77
0.060
 Why?
Quality-Adjusted Life Years
2
2022
122
0.060
 Why?
Age Factors
3
2015
3329
0.060
 Why?
Disease Progression
4
2015
2847
0.060
 Why?
Veterans Disability Claims
1
2006
4
0.060
 Why?
Algorithms
1
2014
1844
0.060
 Why?
Laboratories
1
2007
110
0.060
 Why?
Private Sector
1
2006
50
0.060
 Why?
Employer Health Costs
1
2005
4
0.060
 Why?
Coronary Disease
1
2008
381
0.060
 Why?
Ischemic Attack, Transient
1
2006
71
0.060
 Why?
Metabolic Diseases
1
2007
114
0.060
 Why?
Mexico
1
2026
234
0.060
 Why?
Hallucinations
1
2005
31
0.060
 Why?
Atrial Flutter
1
2005
47
0.060
 Why?
Asthma
2
2007
1774
0.050
 Why?
Double-Blind Method
4
2011
2033
0.050
 Why?
Area Under Curve
1
2005
329
0.050
 Why?
Administration, Inhalation
3
2011
570
0.050
 Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
232
0.050
 Why?
Adrenal Cortex Hormones
1
2007
480
0.050
 Why?
Dasatinib
2
2014
57
0.050
 Why?
Metabolic Syndrome
1
2007
354
0.050
 Why?
Anti-Asthmatic Agents
1
2006
253
0.050
 Why?
Data Collection
1
2006
635
0.050
 Why?
Psychiatric Status Rating Scales
1
2005
539
0.050
 Why?
Colorectal Neoplasms
1
2011
849
0.050
 Why?
Body Weight
1
2007
968
0.050
 Why?
Lung
1
2015
4089
0.050
 Why?
Bevacizumab
2
2014
168
0.050
 Why?
Health Policy
1
2005
398
0.040
 Why?
Diagnosis, Differential
1
2006
1501
0.040
 Why?
Interviews as Topic
1
2005
905
0.040
 Why?
Veterans
1
2013
1614
0.040
 Why?
Dose-Response Relationship, Drug
3
2011
2019
0.040
 Why?
Glucagon-Like Peptides
1
2022
70
0.040
 Why?
Information Storage and Retrieval
1
2021
122
0.040
 Why?
Hematopoietic Stem Cell Transplantation
1
2026
677
0.040
 Why?
Infant
4
2019
10023
0.040
 Why?
Mental Health Services
1
2005
472
0.040
 Why?
Asia
1
2019
71
0.040
 Why?
Azacitidine
1
2021
157
0.040
 Why?
Remission Induction
2
2011
309
0.040
 Why?
France
1
2019
40
0.040
 Why?
Spain
1
2019
49
0.040
 Why?
Incidence
1
2006
2892
0.040
 Why?
Reproducibility of Results
1
2007
3414
0.040
 Why?
Italy
1
2019
114
0.040
 Why?
Germany
1
2019
138
0.040
 Why?
Cyclin-Dependent Kinase 4
1
2018
53
0.030
 Why?
Sex Factors
2
2015
2104
0.030
 Why?
Neutropenia
1
2018
155
0.030
 Why?
Potassium Channel Blockers
1
2017
47
0.030
 Why?
Disease Management
2
2015
650
0.030
 Why?
Models, Econometric
1
2016
34
0.030
 Why?
Bayes Theorem
1
2019
426
0.030
 Why?
Veterans Health
1
2018
189
0.030
 Why?
Itraconazole
1
2016
7
0.030
 Why?
B-Lymphocytes
1
2020
875
0.030
 Why?
Antineoplastic Protocols
1
2014
6
0.030
 Why?
Utilization Review
1
2014
39
0.030
 Why?
Cardiovascular Diseases
1
2007
2172
0.030
 Why?
Early Diagnosis
1
2015
249
0.030
 Why?
Forced Expiratory Volume
1
2015
448
0.030
 Why?
Aspergillus
1
2014
18
0.030
 Why?
Hypothyroidism
1
2014
67
0.030
 Why?
Gene Rearrangement
1
2015
155
0.030
 Why?
Genes, abl
1
2013
4
0.030
 Why?
Cryptococcus
1
2014
16
0.030
 Why?
Medication Therapy Management
1
2014
72
0.030
 Why?
Anemia, Iron-Deficiency
1
2014
62
0.030
 Why?
Peripheral Vascular Diseases
1
2014
104
0.030
 Why?
Socioeconomic Factors
1
2018
1322
0.020
 Why?
Mood Disorders
1
2014
140
0.020
 Why?
Drug Utilization Review
1
2013
61
0.020
 Why?
Myocardium
1
2018
928
0.020
 Why?
Acute Disease
1
2015
1029
0.020
 Why?
Propensity Score
1
2014
373
0.020
 Why?
Atenolol
1
2012
7
0.020
 Why?
Biopsy
1
2015
1079
0.020
 Why?
Nebivolol
1
2012
9
0.020
 Why?
Metoprolol
1
2012
26
0.020
 Why?
Propanolamines
1
2012
40
0.020
 Why?
Carbazoles
1
2012
54
0.020
 Why?
Risk
1
2014
911
0.020
 Why?
Decision Making
1
2019
973
0.020
 Why?
Matched-Pair Analysis
1
2011
37
0.020
 Why?
Nervous System Diseases
1
2014
285
0.020
 Why?
Duloxetine Hydrochloride
1
2011
10
0.020
 Why?
Venlafaxine Hydrochloride
1
2011
12
0.020
 Why?
Cetuximab
1
2011
111
0.020
 Why?
Sitagliptin Phosphate
1
2011
31
0.020
 Why?
Tablets
1
2010
41
0.020
 Why?
State Medicine
1
2009
26
0.020
 Why?
Length of Stay
1
2015
1339
0.020
 Why?
Critical Care
1
2015
695
0.020
 Why?
Epidemiologic Methods
1
2009
89
0.020
 Why?
Blood Glucose
2
2011
2326
0.020
 Why?
Injections, Subcutaneous
1
2009
168
0.020
 Why?
Maximum Tolerated Dose
1
2009
211
0.020
 Why?
Insurance Coverage
1
2010
243
0.020
 Why?
United Kingdom
1
2009
337
0.020
 Why?
Odds Ratio
1
2011
1076
0.020
 Why?
Probability
1
2009
309
0.020
 Why?
Statistics, Nonparametric
1
2009
427
0.020
 Why?
Confidence Intervals
1
2008
331
0.020
 Why?
Canada
1
2009
432
0.020
 Why?
Reference Values
1
2009
794
0.020
 Why?
Sex Distribution
1
2008
386
0.020
 Why?
Longitudinal Studies
1
2014
2942
0.020
 Why?
Prognosis
1
2015
4312
0.020
 Why?
Models, Biological
1
2014
1811
0.010
 Why?
Analysis of Variance
1
2009
1301
0.010
 Why?
RNA, Messenger
1
2013
2815
0.010
 Why?
Tomography, X-Ray Computed
1
2015
2754
0.010
 Why?
Health Status Disparities
1
2008
318
0.010
 Why?
Child, Preschool
2
2007
11790
0.010
 Why?
Emergency Medical Services
1
2007
695
0.010
 Why?
Risk Assessment
1
2009
3729
0.010
 Why?
Body Mass Index
1
2007
2419
0.010
 Why?
Infant, Newborn
1
2006
6399
0.010
 Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (464) concept(s)
_
Co-Authors Expand Description
See all (2) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)